

TABLE 173: NAIVE SVR GENOTYPE 3 WITHOUT CIRRHOSIS: RELATIVE RISKS AND RISK DIFFERENCE FOR AL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

| TREATMENT | REFERENCE | RR (95% CRI) | RD % (95% CRL) |
|---------------------|-------------------------------|-------------------------|------------------------|
| SOF24 + RBV24 | PR48 | 1.31 (1.17 to 1.46) | 22.15 (12.40 to 29.92) |
| DCV12 + SOF12 | | 1.37 (1.23 to 1.52) | 26.25 (16.68 to 33.55) |
| SOF12 + PR12 | | 1.36 (1.18 to 1.51) | 25.69 (12.80 to 33.21) |
| DCV12 + SOF12 | SOF24 + RBV24 | 1.04 (0.95 to 1.15) | 4.14 (−4.73 to 12.46) |
| SOF12 + PR12 | | 1.04 (0.93 to 1.12) | 3.49 (−6.21 to 10.07) |
| SOF12 + PR12 | DCV12 + SOF12 | 1.00 (0.87 to 1.09) | −0.37 (−13.04 to 7.98) |
| | | | |
| Random effect model | Residual deviance | 7.445 vs. 8 data points | |
| | Deviance information criteria | 43.972 | |
| Fixed effect model | Residual deviance | 7.47 vs. 8 data points | |
| | Deviance information criteria | 43.798 | |

Cri = credible interval; DCV = daclatasvir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.